Why is Glaukos stock surging today?

Glaukos (GKOS) reported 3-year data from a study on Epioxa, its corneal cross-linking therapy for keratoconus. The study showed sustained improvement in corneal curvature and visual acuity, with a favorable safety profile. The company markets the only FDA-approved treatment for keratoconus.

Glaukos (GKOS) reported 3-year Phase 3 extension data for Epioxa, showing sustained 1.9D Kmax improvement in keratoconus with no serious adverse events. The results support ongoing commercialization.

Argus lowered its target price for Glaukos Corporation (GKOS) to $168.00. The company focuses on ophthalmic treatments for glaucoma, corneal disorders, and retinal diseases.

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.